Trial Profile
Phase IB/II Study Combining the PI3K Inhibitor Copanlisib With the BTK Inhibitor Ibrutinib in Patients With Recurrent/Refractory Primary CNS Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 25 Dec 2023
Price :
$35
*
At a glance
- Drugs Copanlisib (Primary) ; Ibrutinib (Primary)
- Indications CNS cancer; Lymphoma
- Focus Adverse reactions; Therapeutic Use
- 20 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 03 Jul 2023 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
- 03 Jul 2023 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.